A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of Avastin in combination with
interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal
cell cancer. Patients will receive Avastin (15mg/kg iv) every 3 weeks, interferon alfa-2a 3
times weekly (3 Mio IU sc escalating to 18 Mio sc) and vinblastine (0.1mg/kg iv) every 3
weeks. The anticipated time on study treatment is until tumor progression, and the target
sample size is 100-500 individuals.